[1] Li J, Liang X, You S, et al. Development and validation of a new prognostic score for hepatitis B virus-related acute-on-chronic liver failure[J]. J Hepatol, 2021, 75(5):1104-1115. [2] Liu Y, Dong Y, Wu X, et al. The assessment of mesenchymal stem cells therapy in acute on chronic liver failure and chronic liver disease: a systematic review and meta-analysis of randomized controlled clinical trials[J]. Stem Cell Res Ther, 2022, 13(1):204. [3] Liu X, Zhang J, Wei X, et al. HBV-related acute-on-chronic liver failure with underlying chronic hepatitis has superior survival compared to cirrhosis[J]. Eur J Gastroenterol Hepatol, 2021, 33(1S Suppl 1):e734-e739. [4] Zhang S, Yu J, Rao K, et al. Liver-derived extracellular vesicles from patients with hepatitis B virus-related acute-on-chronic liver failure impair hepatic regeneration by inhibiting on FGFR2 signaling via miR-218-5p[J]. Hepatol Int, 2023, 17(4):833-849. [5] Wu T, Li J, Shao L, et al. Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure[J]. Gut, 2018, 67(12):2181-2191. [6] Khatua C R, Panigrahi S, Mishra D, et al. Acute kidney injury at admission is a better predictor of mortality than its persistence at 48 h in patients with acute-on-chronic liver failure[J]. J Clin Transl Hepatol, 2018, 6(4):396-401. [7] Arora V, Maiwall R, Rajan V, et al. Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure[J]. Hepatology, 2020, 71(2):600-610. [8] Angeli P, Gines P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites[J]. Gut, 2015, 64(4):531-537. [9] Sarin S K, Choudhury A, Sharma M K, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update[J]. Hepatol Int, 2019, 13(4):353-390. [10] Yan H, Wu W, Yang Y, et al. A novel integrated model for end-stage liver disease model predicts short-term prognosis of hepatitis B virus-related acute-on-chronic liver failure patients[J]. Hepatol Res, 2015, 45(4):405-414. [11] Dhanda S, Sandhir R. Blood-brain barrier permeability is exacerbated in experimental model of hepatic encephalopathy via MMP-9 activation and downregulation of tight junction proteins[J]. Mol Neurobiol, 2018, 55(5):3642-3659. [12] 常敏, 孙芳芳, 路遥, 等. 乙型肝炎病毒相关的慢加急性肝衰竭患者发生急性肾损伤的临床特点及预后研究[J]. 中华实验和临床病毒学杂志, 2021, 35(4):378-383. [13] 黄少军, 付文荣, 汪晶晶, 等. CXCL10基因rs56061981单核苷酸多态性与HBV相关慢加急性肝衰竭易感性及严重程度的关系[J]. 中华实验和临床病毒学杂志, 2022, 36(1):97-102. [14] 刘婉姝, 申力军, 田华, 等. 慢加急性肝衰竭ABC分型的预后及MELD 3.0和COSSH-ACLF Ⅱ对预后评估价值[J]. 中华肝脏病杂志, 2022, 30(9):976-980. [15] 李晨, 游绍莉, 刘鸿凌, 等. 基线MELD、MELD-Na、iMELD 3种模型对乙型肝炎病毒相关慢加急性肝衰竭患者近期预后的评估价值[J]. 中华危重病急救医学, 2014, 26(8):539-543. |